» Articles » PMID: 4854942

The Manifesting Carrier in Duchenne Muscular Dystrophy

Overview
Journal Clin Genet
Specialty Genetics
Date 1974 Jan 1
PMID 4854942
Citations 40
Authors
Affiliations
Soon will be listed here.
Citing Articles

Deep characterization of females with heterozygous Duchenne muscular dystrophy mutations.

Riguzzi P, Sabbatini D, Fusto A, Vianello S, Merlo B, Zangaro V J Neurol. 2025; 272(3):244.

PMID: 40035839 PMC: 11880153. DOI: 10.1007/s00415-025-12987-4.


Treatment with ataluren in four symptomatic Duchenne carriers. A pilot study.

Dori A, Scutifero M, Passamano L, Zoppi D, Ruggiero L, Trabacca A Acta Myol. 2024; 43(1):8-15.

PMID: 38586166 PMC: 10997039. DOI: 10.36185/2532-1900-398.


Phenotypic features of genetically modified -XX pigs.

Okamoto K, Matsunari H, Nakano K, Umeyama K, Hasegawa K, Uchikura A Regen Ther. 2023; 24:451-458.

PMID: 37772130 PMC: 10523442. DOI: 10.1016/j.reth.2023.09.010.


Caregiver Burden with Duchenne and Becker Muscular Dystrophy in Japan: A Clinical Observation Study.

Ishizaki M, Kobayashi M, Hashimoto H, Nakamura A, Maeda Y, Ueyama H Intern Med. 2023; 63(3):365-372.

PMID: 37344421 PMC: 10901721. DOI: 10.2169/internalmedicine.9372-22.


Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up.

Dori A, Guglieri M, Scutifero M, Passamano L, Trabacca A, Politano L Acta Myol. 2022; 40(4):152-157.

PMID: 35047755 PMC: 8744011. DOI: 10.36185/2532-1900-058.